Pre-made Pacanalotamab benchmark antibody ( Bispecific scFv, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-421
Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pacanalotamab is an anti-BCMA-anti-CD3-bispecific-antibody, where the bispecific T-cell engager (BiTE) binds to the CD3 epsilon subunit of the T cell receptor complex on T-cells and to B-cell maturation antigen (BCMA), a membrane-bound receptor on plasma cells, resulting in activation of T cells against BCMA.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Multiple myeloma|
|Development Tech||BiTE Technology|